Trial Profile
A Phase 3 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Didanosine; Lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.